Promising results have been reported in a phase I trial in CD30-positive PTCL, using either BV administered sequentially with CHOP, or BV in combination with CHP. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.